Core Insights - Foghorn Therapeutics is advancing its pipeline, particularly focusing on FHD-909, a first-in-class oral SMARCA2 selective inhibitor, which is currently in a Phase 1 dose escalation trial targeting non-small cell lung cancer (NSCLC) [1][3][4] - The company has shown promising preclinical data indicating synergistic effects of FHD-909 when combined with pembrolizumab and KRAS inhibitors, suggesting significant potential in treating difficult-to-treat NSCLC [2][4] - Foghorn's selective degrader programs targeting CBP, EP300, and ARID1B are progressing well, with updates expected in Q4 2025 and an IND application for the Selective CBP degrader anticipated in 2026 [2][6][12] Financial Overview - As of June 30, 2025, Foghorn reported cash, cash equivalents, and marketable securities totaling $198.7 million, providing a cash runway into 2028 [1][18] - Collaboration revenue for the three months ended June 30, 2025, was $7.6 million, an increase from $6.9 million in the same period in 2024, driven by advancements in programs under the Lilly Collaboration Agreement [10][21] - The net loss for the three months ended June 30, 2025, was $17.9 million, compared to a net loss of $23.0 million for the same period in 2024, indicating improved financial performance [18][21] Pipeline and Development Programs - FHD-909 is designed to selectively inhibit SMARCA2, which is crucial for the survival of tumors with SMARCA4 mutations, and has shown significant anti-tumor activity in preclinical models [3][13] - The Selective CBP degrader program targets EP300-mutated cancer cells and has shown encouraging activity in ER+ breast cancer, with potential applications beyond EP300-mutant tumors [2][6][11] - The Selective EP300 degrader is being developed for hematological malignancies and prostate cancer, with updates expected in Q4 2025 [7][11] - The Selective ARID1B degrader targets ARID1B in ARID1A-mutated cancers, which are prevalent in various solid tumors, and has achieved selective degradation in preclinical studies [8][12] Strategic Collaborations - Foghorn is collaborating with Lilly under a 50/50 co-development and co-commercialization agreement for FHD-909, which is currently enrolling patients in a Phase 1 trial [4][5] - The collaboration aims to develop novel oncology medicines, leveraging both companies' strengths in drug development [4][5]

FHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population Data presented at AACR show synergistic activity with FHD-909 in combination with pembrolizumab and KRAS inhibitors and support clinical exploration Selective CBP degrader on track for IND-enabling studies, targeting IND in 2026 Continued progress on Selective EP300 degrader and Selective ARID1B degrader with program updates expected in H2 ...

Core Insights - Foghorn Therapeutics Inc. is advancing its clinical-stage pipeline, particularly focusing on FHD-909, a selective SMARCA2 inhibitor, which is currently in Phase 1 trials targeting SMARCA4 mutated cancers, primarily non-small cell lung cancer (NSCLC) [1][2][5] Group 1: FHD-909 Program - FHD-909 demonstrates synergistic anti-tumor activity when combined with chemotherapy, KRAS inhibitors, and pembrolizumab, warranting further clinical exploration [1][4] - The ongoing Phase 1 trial of FHD-909 is evaluating patients with SMARCA4 mutations who have exhausted standard treatment options, with a focus on NSCLC and other advanced solid tumors [5][9] - Preclinical studies indicate that FHD-909 selectively inhibits SMARCA4 mutant cancer cells and shows robust anti-tumor efficacy in xenograft models [4][13] Group 2: Selective CBP and EP300 Degrader Programs - The Selective CBP degrader program shows promise in preclinical models, indicating potential benefits in solid tumors beyond EP300-mutant cancers [6][10] - Initial preclinical data for the Selective EP300 degrader program suggests significant anti-cancer activity in hematological malignancies, with ongoing characterization of its therapeutic potential [7][11] - The Selective ARID1B degrader program is also in development, targeting a synthetic lethal mechanism implicated in up to 5% of all solid tumors [8][16] Group 3: Upcoming Events and Presentations - Foghorn management will hold a virtual investor event on April 29, 2025, to discuss pipeline updates, including the FHD-909 program and other ongoing research efforts [2][12] - A poster presentation on the Selective EP300 degrader program is scheduled for April 30, 2025, at the AACR Annual Meeting [2][7]

Core Insights - Foghorn Therapeutics is set to present new preclinical combination data for FHD-909, a potential first-in-class selective SMARCA2 inhibitor targeting non-small cell lung cancer (NSCLC) [1][2] - The company will also share updates on its Selective CBP and EP300 degrader programs, along with an overview of the Selective ARID1B degrader program during a virtual investor event on April 29, 2025 [1][2][3] Company Overview - FHD-909 (LY4050784) is an allosteric, orally available small molecule that selectively inhibits the ATPase activity of SMARCA2, showing significant anti-tumor activity in preclinical studies involving SMARCA4 mutant lung tumor models [4] - Foghorn Therapeutics focuses on developing a novel class of medicines that target genetically determined dependencies within the chromatin regulatory system, utilizing its Gene Traffic Control platform to identify and validate drug targets [5]